# AI & Computation

Source: https://onco.cc/fronts/ai-computation/  
OnCo record `ai-computation` (Front). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Software that reads scans and slides, predicts outcomes, designs drugs, and matches patients to trials.

## Summary

AI and computation collects the software that reads scans and slides, predicts outcomes, designs drugs and matches patients to trials. It covers FDA-cleared digital pathology risk tools such as ArteraAI, radiology triage and screening models, pathology and radiology foundation models, multimodal patient-level models, AI-driven target discovery and ADC design, and LLM-based trial matching and tumour-board support. Listed technologies include federated learning, CHIEF, Phikon, CT-FM, MedSAM, Aidoc CARE, CellFM, GenePT, Nucleotide Transformer, Enformer and Borzoi, and NVIDIA BioNeMo. Records pointing here include AI in radiology, digital pathology and AI, AI trial matching, AI-driven drug and target discovery, and the companies Tempus AI, BostonGene, Artera, Paige AI, PathAI and Owkin.

## Fields

- Kind: Front
- Last checked: 2026-09-04

## Sources

- NCI: Artificial intelligence in cancer research: https://www.cancer.gov/research/infrastructure/artificial-intelligence

## Connected records

- technologies: [Adaptive therapy (evolution-based dosing)](https://onco.cc/technologies/adaptive-therapy-dynamics/), [Agent-based and multicellular simulations](https://onco.cc/technologies/agent-based-tumour-models/), [AI auto-contouring and adaptive planning](https://onco.cc/technologies/auto-contouring-ai/), [AI compute and model platforms for oncology](https://onco.cc/technologies/ai-compute-platforms/), [AI in radiology](https://onco.cc/technologies/radiology-ai-screening/), [AI polyp detection in colonoscopy](https://onco.cc/technologies/ai-endoscopy-detection/), [AI scoring of biomarkers and grade on pathology slides](https://onco.cc/technologies/ai-pathology-scoring/), [AI trial matching & clinical decision support](https://onco.cc/technologies/ai-trial-matching/), [AI-assisted mammography screening](https://onco.cc/technologies/ai-mammography-screening/), [AI-driven drug & target discovery](https://onco.cc/technologies/ai-drug-design/), [Aidoc CARE (clinical radiology foundation model)](https://onco.cc/technologies/aidoc-care/), [AlphaFold 3](https://onco.cc/technologies/alphafold3/), [AlphaGenome](https://onco.cc/technologies/alphagenome/), [AlphaMissense](https://onco.cc/technologies/alphamissense/), [Angiogenesis and vascular normalisation models](https://onco.cc/technologies/angiogenesis-models/), [Asking people how they are, every week, as a treatment in its own right](https://onco.cc/technologies/rejuv-measure-epro-as-treatment/), [Atlas (Aignostics, Mayo Clinic, Charité)](https://onco.cc/technologies/atlas-aignostics/), [BioEmu (Microsoft)](https://onco.cc/technologies/bioemu/), [Body-surface-area dosing](https://onco.cc/technologies/body-surface-area-dosing/), [Boltz-1 / Boltz-2 (MIT, open)](https://onco.cc/technologies/boltz/), [Cancer cell line encyclopedias and dependency maps](https://onco.cc/technologies/cancer-cell-line-encyclopedias/), [Cancer registries and population surveillance](https://onco.cc/technologies/cancer-registries-surveillance/), [Cancer variant knowledgebases and molecular tumour boards](https://onco.cc/technologies/variant-knowledgebases/), [Cell-therapy orchestration and chain-of-identity software](https://onco.cc/technologies/cell-therapy-orchestration-software/), [Cell2Sentence / C2S-Scale (Yale, Google)](https://onco.cc/technologies/c2s-scale/), [CellFM](https://onco.cc/technologies/cellfm/), [Chai-1 / Chai-2](https://onco.cc/technologies/chai-1/), [CHIEF (Harvard, Yu Lab)](https://onco.cc/technologies/chief/), [Clinical NGS bioinformatics and variant interpretation](https://onco.cc/technologies/ngs-bioinformatics-software/), [Clinical trial software (EDC, eCOA, CTMS, RTSM)](https://onco.cc/technologies/clinical-trial-software/), [Clonal evolution and branching models](https://onco.cc/technologies/clonal-evolution-models/), [Contract research organisations (CROs)](https://onco.cc/technologies/contract-research-organisations/), [CT-FM (whole-body CT foundation model)](https://onco.cc/technologies/ct-fm/), [Decentralised and hybrid clinical trials](https://onco.cc/technologies/decentralised-clinical-trials/), [Dermoscopy, total-body photography & AI skin analysis](https://onco.cc/technologies/dermoscopy-ai/), [Digital pathology & AI](https://onco.cc/technologies/digital-pathology-ai/), [Digital twins and virtual control arms](https://onco.cc/technologies/digital-twins-trials/), [Electronic patient-reported outcome (ePRO) symptom monitoring](https://onco.cc/technologies/epro-symptom-monitoring/), [Electronic patient-reported outcomes and remote monitoring](https://onco.cc/technologies/remote-patient-monitoring/), [Enformer and Borzoi (DeepMind, Calico)](https://onco.cc/technologies/enformer-borzoi/), [ESM3 (EvolutionaryScale)](https://onco.cc/technologies/esm3/), [Evo 2 (Arc Institute, NVIDIA)](https://onco.cc/technologies/evo2/), [Evolutionary dynamics of drug resistance](https://onco.cc/technologies/drug-resistance-dynamics/), [Evolutionary game theory in cancer](https://onco.cc/technologies/evolutionary-game-theory-cancer/), [Federated learning and privacy-preserving AI](https://onco.cc/technologies/federated-learning-medical-ai/), [Foresight (generative EHR model)](https://onco.cc/technologies/foresight-ehr/), [GEARS and perturbation prediction benchmarks](https://onco.cc/technologies/gears/), [Geneformer](https://onco.cc/technologies/geneformer/), [GenePT](https://onco.cc/technologies/genept/), [Genomics cloud and secure research environments](https://onco.cc/technologies/genomics-cloud-platforms/), [Goldie-Coldman model of resistance](https://onco.cc/technologies/goldie-coldman-model/), [Gompertzian tumour growth](https://onco.cc/technologies/gompertzian-growth-model/), [H-optimus (Bioptimus)](https://onco.cc/technologies/h-optimus/), [Hibou (HistAI)](https://onco.cc/technologies/hibou/), [Log-kill hypothesis (Skipper)](https://onco.cc/technologies/log-kill-hypothesis/), [Mathematical models of cancer (mathematical oncology)](https://onco.cc/technologies/mathematical-oncology/), [Med-Gemini and MedLM (Google)](https://onco.cc/technologies/med-gemini/), [MedSAM / SAM-Med3D (segment anything for medicine)](https://onco.cc/technologies/medsam/), [Merlin (Stanford abdominal CT vision-language model)](https://onco.cc/technologies/merlin-ct/), [Metastatic seeding and dormancy models](https://onco.cc/technologies/metastasis-seeding-models/), [Midnight (kaiko.ai)](https://onco.cc/technologies/kaiko-midnight/), [Mirai (MIT breast cancer risk from mammograms)](https://onco.cc/technologies/mirai/), [MUSK (Stanford, vision-language pathology)](https://onco.cc/technologies/musk/), [Nicheformer (spatial single-cell)](https://onco.cc/technologies/nicheformer/), [Norton-Simon hypothesis and dose-dense chemotherapy](https://onco.cc/technologies/norton-simon-hypothesis/), [Nucleotide Transformer (InstaDeep)](https://onco.cc/technologies/nucleotide-transformer/), [NVIDIA BioNeMo](https://onco.cc/technologies/bionemo/), [Oncology EHR and real-world data platforms](https://onco.cc/technologies/oncology-real-world-data/), [Oncology EHR modules and treatment pathways](https://onco.cc/technologies/hospital-information-systems-oncology/), [Oncology information and record-and-verify systems (ARIA, MOSAIQ)](https://onco.cc/technologies/oncology-information-systems/), [Pathology & radiology foundation models](https://onco.cc/technologies/pathology-foundation-model/), [Patient digital twins](https://onco.cc/technologies/digital-twin-patient-models/), [Pharmacokinetic and pharmacodynamic modelling](https://onco.cc/technologies/pkpd-modelling/), [Phenom-2 and Recursion OS](https://onco.cc/technologies/phenom-2/), [Phikon / Phikon-v2 (Owkin)](https://onco.cc/technologies/phikon/), [PLUTO (PathAI)](https://onco.cc/technologies/pluto/), [Polygenic risk scores for cancer](https://onco.cc/technologies/polygenic-risk-scores/), [Proliferation-invasion (reaction-diffusion) models of glioma](https://onco.cc/technologies/reaction-diffusion-glioma-model/), [Prov-GigaPath (Microsoft, Providence)](https://onco.cc/technologies/prov-gigapath/), [Quantitative systems pharmacology (QSP)](https://onco.cc/technologies/quantitative-systems-pharmacology/), [RadFM (generalist radiology foundation model)](https://onco.cc/technologies/radfm/), [Radiomics](https://onco.cc/technologies/radiomics/), [Radiotherapy treatment planning and QA software](https://onco.cc/technologies/treatment-planning-systems/), [Residual disease kinetics (BCR-ABL halving and ctDNA slopes)](https://onco.cc/technologies/mrd-kinetics-models/), [RFdiffusion / RFdiffusion2 and ProteinMPNN (Baker Lab)](https://onco.cc/technologies/rfdiffusion/), [scFoundation (BioMap)](https://onco.cc/technologies/scfoundation/), [scGPT](https://onco.cc/technologies/scgpt/), [Solid stress and tumour mechanobiology models](https://onco.cc/technologies/tumour-mechanics-models/), [Spatial-omics-guided treatment selection](https://onco.cc/technologies/spatial-omics-guided-therapy/), [State (Arc Institute perturbation model)](https://onco.cc/technologies/state-arc/), [Sybil (MIT/MGH lung cancer risk from CT)](https://onco.cc/technologies/sybil/), [Telehealth and hospital-at-home in oncology](https://onco.cc/technologies/telehealth-oncology/), [Tempus multimodal models](https://onco.cc/technologies/tempus-multimodal/), [The four Rs and accelerated repopulation](https://onco.cc/technologies/fractionation-repopulation-models/), [TITAN (whole-slide multimodal model)](https://onco.cc/technologies/titan/), [TranscriptFormer and rBio (CZI virtual cell models)](https://onco.cc/technologies/transcriptformer/), [Tumour control and normal tissue complication probability (TCP and NTCP)](https://onco.cc/technologies/tumour-control-probability-models/), [Tumour volume doubling time](https://onco.cc/technologies/tumour-doubling-time/), [Tumour-immune dynamics models](https://onco.cc/technologies/immune-tumour-dynamics-models/), [UNI and CONCH (Harvard, Mahmood Lab)](https://onco.cc/technologies/uni-conch/), [Universal Cell Embedding (UCE)](https://onco.cc/technologies/universal-cell-embedding/), [Virchow / Virchow2 (Paige, MSK)](https://onco.cc/technologies/virchow/), [Wearables and step counts: measuring what someone actually does](https://onco.cc/technologies/rejuv-measure-wearables-and-step-counts/), [What has actually been implemented since those trials, and what has not](https://onco.cc/technologies/rejuv-measure-epro-implementation/), [Whole-slide scanners and image management](https://onco.cc/technologies/whole-slide-scanners/)
- companies: [Aidoc](https://onco.cc/companies/aidoc/), [Aignostics](https://onco.cc/companies/aignostics/), [Aluna](https://onco.cc/companies/aluna/), [Aqemia](https://onco.cc/companies/aqemia/), [Artera](https://onco.cc/companies/artera/), [Ataraxis AI](https://onco.cc/companies/ataraxis-ai/), [Belong.Life](https://onco.cc/companies/belong-life/), [BigHat Biosciences](https://onco.cc/companies/bighat-biosciences/), [Bioptimus](https://onco.cc/companies/bioptimus/), [Blank Bio](https://onco.cc/companies/blank-bio/), [BostonGene](https://onco.cc/companies/bostongene/), [Cambridge Cancer Genomics (CCG.ai)](https://onco.cc/companies/cambridge-cancer-genomics/), [Canopy](https://onco.cc/companies/canopy/), [Careology](https://onco.cc/companies/careology/), [Carevive Systems](https://onco.cc/companies/carevive-systems/), [Chai Discovery](https://onco.cc/companies/chai-discovery/), [Chan Zuckerberg Initiative (Biohub)](https://onco.cc/companies/chan-zuckerberg-initiative/), [Clario](https://onco.cc/companies/clario/), [ConcertAI](https://onco.cc/companies/concertai/), [COTA](https://onco.cc/companies/cota-healthcare/), [CytoReason](https://onco.cc/companies/cytoreason/), [Datavant](https://onco.cc/companies/datavant/), [Deep 6 AI](https://onco.cc/companies/deep-6-ai/), [DNAnexus](https://onco.cc/companies/dnanexus/), [Epic Systems](https://onco.cc/companies/epic-systems/), [Evaxion](https://onco.cc/companies/evaxion/), [EvolutionaryScale](https://onco.cc/companies/evolutionaryscale/), [Exscientia](https://onco.cc/companies/exscientia/), [Flatiron Health (Roche)](https://onco.cc/companies/flatiron-health/), [Fortrea](https://onco.cc/companies/fortrea/), [Generate:Biomedicines](https://onco.cc/companies/generate-biomedicines/), [Google (Health, DeepMind, Verily)](https://onco.cc/companies/google-health/), [Google DeepMind (and Google Research)](https://onco.cc/companies/google-deepmind/), [HistAI](https://onco.cc/companies/histai/), [Ibex Medical Analytics](https://onco.cc/companies/ibex-medical-analytics/), [iCAD (RadNet)](https://onco.cc/companies/icad/), [ICON plc](https://onco.cc/companies/icon-plc/), [Iktos](https://onco.cc/companies/iktos/), [Imagene AI](https://onco.cc/companies/imagene-ai/), [Immunai](https://onco.cc/companies/immunai/), [Indica Labs](https://onco.cc/companies/indica-labs/), [Insilico Medicine](https://onco.cc/companies/insilico-medicine/), [IQVIA](https://onco.cc/companies/iqvia/), [Isomorphic Labs](https://onco.cc/companies/isomorphic-labs/), [kaiko.ai](https://onco.cc/companies/kaiko-ai/), [Kheiron Medical Technologies](https://onco.cc/companies/kheiron-medical-technologies/), [Komodo Health](https://onco.cc/companies/komodo-health/), [Lila Sciences](https://onco.cc/companies/lila-sciences/), [Limbus AI](https://onco.cc/companies/limbus-ai/), [Liyfe](https://onco.cc/companies/liyfe/), [Lunit](https://onco.cc/companies/lunit/), [Massive Bio](https://onco.cc/companies/massive-bio/), [Medable](https://onco.cc/companies/medable/), [Medidata (Dassault Systèmes)](https://onco.cc/companies/medidata/), [Mednet (theMednet)](https://onco.cc/companies/mednet/), [Medpace](https://onco.cc/companies/medpace/), [Microsoft (Health & Life Sciences)](https://onco.cc/companies/microsoft/), [Microsoft (Research and Health AI)](https://onco.cc/companies/microsoft-research/), [MVision AI](https://onco.cc/companies/mvision-ai/), [Noetik](https://onco.cc/companies/noetik/), [Nucleai](https://onco.cc/companies/nucleai/), [Nucleo](https://onco.cc/companies/nucleo-research/), [NVIDIA](https://onco.cc/companies/nvidia/), [Onc.AI](https://onco.cc/companies/onc-ai/), [OncoHealth](https://onco.cc/companies/oncohealth/), [Optellum](https://onco.cc/companies/optellum/), [Oracle Health (Cerner) & Oracle Life Sciences](https://onco.cc/companies/oracle-health-sciences/), [Origin Bio](https://onco.cc/companies/origin-bio/), [Outcomes4Me](https://onco.cc/companies/outcomes4me/), [Owkin](https://onco.cc/companies/owkin/), [Paige AI](https://onco.cc/companies/paige/), [Parexel](https://onco.cc/companies/parexel/), [PathAI](https://onco.cc/companies/pathai/), [Pathos AI](https://onco.cc/companies/pathos-ai/), [Patient Data Vault (data-vault.health)](https://onco.cc/companies/patient-data-vault/), [Perimeter Medical Imaging AI](https://onco.cc/companies/perimeter-medical-imaging-ai/), [Proscia](https://onco.cc/companies/proscia/), [Radformation](https://onco.cc/companies/radformation/), [Recursion Pharmaceuticals](https://onco.cc/companies/recursion/), [Reimagine Care](https://onco.cc/companies/reimagine-care/), [Reverie Labs](https://onco.cc/companies/reverie-labs/), [Science 37 (eMed)](https://onco.cc/companies/science-37/), [ScreenPoint Medical](https://onco.cc/companies/screenpoint-medical/), [Serinus Biosciences](https://onco.cc/companies/serinus-biosciences/), [SOPHiA GENETICS](https://onco.cc/companies/sophia-genetics/), [Strand AI](https://onco.cc/companies/strand-ai/), [TailorMed](https://onco.cc/companies/tailormed/), [Tempus AI](https://onco.cc/companies/tempus/), [TheraPanacea](https://onco.cc/companies/therapanacea/), [Therapixel](https://onco.cc/companies/therapixel/), [Trial Library](https://onco.cc/companies/trial-library/), [TriNetX](https://onco.cc/companies/trinetx/), [Triomics](https://onco.cc/companies/triomics/), [Turbine](https://onco.cc/companies/turbine/), [Valar Labs](https://onco.cc/companies/valar-labs/), [Valo Health](https://onco.cc/companies/valo-health/), [Vara](https://onco.cc/companies/vara/), [Veeva Systems](https://onco.cc/companies/veeva-systems/), [Velsera (Seven Bridges and Pierian)](https://onco.cc/companies/velsera/), [Vevo Therapeutics](https://onco.cc/companies/vevo-therapeutics/), [Volpara Health](https://onco.cc/companies/volpara-health/), [Xaira Therapeutics](https://onco.cc/companies/xaira-therapeutics/), [Y Combinator](https://onco.cc/companies/y-combinator/)
- journals: [JCO clinical cancer informatics](https://onco.cc/journals/jco-clinical-cancer-informatics/), [JMIR cancer](https://onco.cc/journals/jmir-cancer/)
- key papers: [A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications](https://onco.cc/key-papers/paper-wright-lymphgen-genetic-subtypes-dlbcl-cancer-cell-2020/), [AlphaFold 2: predicting protein structures to near-experimental accuracy](https://onco.cc/key-papers/paper-alphafold2-jumper-nature-2021/), [Integrative genomic profiling of human prostate cancer](https://onco.cc/key-papers/paper-taylor-integrative-genomic-profiling-cancer-cell-2010/), [MASAI: AI-supported mammography screening finds more cancers with half the radiologist workload](https://onco.cc/key-papers/paper-masai-lancet-oncol-2023/), [The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma](https://onco.cc/key-papers/paper-rosenwald-molecular-profiling-dlbcl-nejm-2002/)
- bottlenecks: [AI that is built but not validated or deployed](https://onco.cc/bottlenecks/b-ai-validation/), [Data silos](https://onco.cc/bottlenecks/b-data-silos/), [Not enough oncologists, nurses, pathologists, physicists](https://onco.cc/bottlenecks/b-workforce/)
- ideas: [A cancer data donor card: patient-controlled donation of records for research](https://onco.cc/ideas/idea-data-donor-card/), [A chatbot for pre-test genetic counselling so counsellors see only who needs them](https://onco.cc/ideas/idea-prev-genetic-counselling-chatbot/), [A common consent and material transfer template for tumour biobanks](https://onco.cc/ideas/idea-data-common-biobank-consent-mta/), [A consented commons of surgical video linked to pathology and outcomes](https://onco.cc/ideas/idea-data-surgical-video-commons/), [A dedicated fund for randomised trials of cancer AI with patient outcomes](https://onco.cc/ideas/idea-data-prospective-ai-trials-fund/), [A digital second-opinion network answering community oncologists within 72 hours](https://onco.cc/ideas/idea-data-72-hour-second-opinion-network/), [A liability framework for clinical AI: safe harbour for clinicians, liability for makers](https://onco.cc/ideas/idea-data-ai-liability-safe-harbour/), [A machine-readable treatment summary handed to every patient and readable by any hospital](https://onco.cc/ideas/idea-acc-portable-treatment-summary/), [A mandatory silent (shadow) trial before any cancer AI goes live](https://onco.cc/ideas/idea-data-silent-trial-before-deployment/), [A monthly-updated benchmark for AI answers to oncology questions with citation accuracy](https://onco.cc/ideas/idea-data-living-llm-oncology-benchmark/), [A national cancer data space with one legal front door](https://onco.cc/ideas/idea-data-national-cancer-data-space/), [A national repository of radiotherapy dose plans linked to outcomes](https://onco.cc/ideas/idea-data-radiotherapy-dose-repository/), [A neutral public evaluator for cancer AI, on the model of NIST](https://onco.cc/ideas/idea-data-neutral-ai-evaluator/), [A patient-held cancer record that travels across providers and borders](https://onco.cc/ideas/idea-data-patient-held-cancer-record/), [A plain-language explainer for every guideline recommendation, in every major language](https://onco.cc/ideas/idea-data-patient-explainers-per-recommendation/), [A plain-language summary of every cancer trial result within a year](https://onco.cc/ideas/idea-data-plain-language-summary-mandate/), [A pre-competitive consortium to train a shared multimodal cancer foundation model](https://onco.cc/ideas/idea-data-precompetitive-cancer-foundation-model/), [A pre-registered standard for emulating trials with real-world data](https://onco.cc/ideas/idea-data-target-trial-emulation-standard/), [A public API serving the current standard of care for any cancer, stage and biomarker](https://onco.cc/ideas/idea-data-standard-of-care-api/), [A public registry of every AI model used in cancer care](https://onco.cc/ideas/idea-data-clinical-ai-model-registry/), [A public registry of unanswered clinical questions linked to funding calls](https://onco.cc/ideas/idea-data-unanswered-questions-registry/), [A public tracker of how long each country takes to adopt new evidence](https://onco.cc/ideas/idea-data-evidence-to-adoption-tracker/), [A randomised trial of AI scribes in oncology clinics measuring errors and time](https://onco.cc/ideas/idea-data-llm-documentation-rct-oncology/), [A randomised trial of AI-generated treatment recommendations versus tumour boards](https://onco.cc/ideas/idea-data-ai-vs-tumour-board-rct/), [A real-world sequencing analysis within a year of every new approval](https://onco.cc/ideas/idea-data-sequencing-analysis-per-approval/), [A regulatory sandbox for continuously learning cancer AI](https://onco.cc/ideas/idea-data-regulatory-sandbox-adaptive-ai/), [A standard evaluation pathway for AI-assisted pathology, from reader study to deployment](https://onco.cc/ideas/idea-data-ai-pathology-evaluation-standard/), [A standard for monitoring AI performance drift with pause thresholds](https://onco.cc/ideas/idea-data-drift-monitoring-standard/), [A structured registry for every off-label cancer drug use](https://onco.cc/ideas/idea-data-off-label-outcomes-registry/), [A synthetic twin of every restricted cancer dataset for code development](https://onco.cc/ideas/idea-data-synthetic-companion-datasets/), [A tumour board assistant that cites its evidence and tracks outcomes](https://onco.cc/ideas/idea-data-tumour-board-evidence-assistant/), [Accredited trusted research environments with curated cancer tables](https://onco.cc/ideas/idea-data-accredited-tre-network/), [Ambient AI note-taking to give oncologists back a day a week](https://onco.cc/ideas/idea-acc-ambient-ai-documentation-oncology/), [An automatic electronic frailty index inside the oncology record](https://onco.cc/ideas/idea-acc-electronic-frailty-index-oncology/), [An international consortium pooling the outcome of every treated child with cancer](https://onco.cc/ideas/idea-data-paediatric-rwe-consortium/), [An open foundation model of the cancer cell trained on perturbation data](https://onco.cc/ideas/idea-data-open-cell-foundation-model/), [An open knowledge graph linking trials, results, biomarkers, drugs and recommendations](https://onco.cc/ideas/idea-data-open-evidence-knowledge-graph/), [An open library pairing completed cancer trials with real-world emulations](https://onco.cc/ideas/idea-data-rwe-rct-calibration-library/), [Automatic flagging of retracted or corrected evidence in guidelines and decision support](https://onco.cc/ideas/idea-data-retraction-propagation/), [Automatic weekly linkage of cancer registries to deaths, prescriptions and imaging](https://onco.cc/ideas/idea-data-automatic-outcome-linkage/), [Broad research consent as a routine step of the cancer pathway](https://onco.cc/ideas/idea-data-consent-in-the-pathway/), [Certify every oncology software product for a standard bulk data export](https://onco.cc/ideas/idea-data-oncology-api-certification/), [Decision support that cites the exact trial and guideline line it relies on](https://onco.cc/ideas/idea-data-provenance-first-decision-support/), [Deposit trial results as structured data, not just PDFs](https://onco.cc/ideas/idea-data-structured-trial-results-deposit/), [Digital twins for treatment selection, validated by predicting before observing](https://onco.cc/ideas/idea-data-digital-twin-predict-then-observe/), [Digitise the nation's pathology slides and link them to outcomes](https://onco.cc/ideas/idea-data-national-slide-archive/), [Dynamic consent with usage receipts](https://onco.cc/ideas/idea-data-dynamic-consent-app/), [End the abstract-to-paper gap: require full results with any conference presentation](https://onco.cc/ideas/idea-data-full-data-with-abstract/), [Enforce individual participant data sharing as a condition of publication and funding](https://onco.cc/ideas/idea-data-ipd-deposit-enforcement/), [Every AI output logged in the record with input hash, version and clinician response](https://onco.cc/ideas/idea-data-ai-audit-trail-in-ehr/), [Every patient on an accelerated-approval drug enrolled in a registry until confirmation](https://onco.cc/ideas/idea-data-accelerated-approval-registry-condition/), [Every tumour genomic report machine-readable and deposited nationally](https://onco.cc/ideas/idea-data-structured-genomic-reports/), [Expert-verified translation of guideline updates into 20 languages within 30 days](https://onco.cc/ideas/idea-data-rapid-guideline-translation/), [External validation at five or more sites in two countries before clearance](https://onco.cc/ideas/idea-data-multisite-validation-precondition/), [Federated training of pathology and radiology models across hospitals](https://onco.cc/ideas/idea-data-federated-learning-imaging/), [Follow every trial participant for 30 years through registry linkage](https://onco.cc/ideas/idea-data-registry-follow-up-of-trial-participants/), [Fund expert editors for the cancer pages of Wikipedia and Wikidata](https://onco.cc/ideas/idea-data-wikipedia-oncology-editors/), [Funded living systematic reviews for every major cancer indication](https://onco.cc/ideas/idea-data-funded-living-systematic-reviews/), [Good practice standards and inspection for real-world data sources](https://onco.cc/ideas/idea-data-gcp-for-real-world-data/), [In silico trials to prioritise combinations, scored against later real trials](https://onco.cc/ideas/idea-data-in-silico-trials-calibrated/), [Link every national cancer registry to tumour genomics](https://onco.cc/ideas/idea-data-registry-genomics-linkage-programme/), [Link single-cell and spatial tumour atlases to clinical outcomes](https://onco.cc/ideas/idea-data-atlas-to-outcome-linkage/), [Linked prescribing and outcome data to find drug interactions with cancer therapy](https://onco.cc/ideas/idea-data-linked-pharmacovigilance-interactions/), [Live guideline-concordance dashboards for every tumour board, generated from the record](https://onco.cc/ideas/idea-acc-guideline-concordance-dashboards/), [Living guidelines published as versioned, computable rules](https://onco.cc/ideas/idea-data-computable-living-guidelines/), [Mandatory post-market performance reporting for cancer AI](https://onco.cc/ideas/idea-data-ai-post-market-performance-reporting/), [Mandatory real-world reporting for patients excluded from pivotal trials](https://onco.cc/ideas/idea-data-excluded-populations-rwe-mandate/), [Mandatory subgroup performance reporting for cancer AI](https://onco.cc/ideas/idea-data-subgroup-performance-reporting-mandate/), [Map trial case report forms to the registry standard so trial and routine data join](https://onco.cc/ideas/idea-data-trial-to-registry-bridge/), [Micro-learning pushed to community oncologists within 30 days of a practice change](https://onco.cc/ideas/idea-data-thirty-day-practice-change-learning/), [No mCODE, no payment: tie oncology reimbursement to a minimal structured record](https://onco.cc/ideas/idea-data-mcode-payment-condition/), [Offline decision support for generalists treating common cancers in low-resource settings](https://onco.cc/ideas/idea-data-offline-cds-lmic-generalists/), [One certified open-source de-identification pipeline for scans and slides](https://onco.cc/ideas/idea-data-open-deidentification-pipeline/), [One legal framework for pooling rare cancer data across borders](https://onco.cc/ideas/idea-data-cross-border-rare-cancer-pool/), [One outcome record for every donated or discounted cancer drug pack](https://onco.cc/ideas/idea-data-access-programme-outcomes/), [Open licences for publicly funded cancer guidelines](https://onco.cc/ideas/idea-data-open-licensed-guidelines/), [Open-source cancer registry-in-a-box for low-resource settings](https://onco.cc/ideas/idea-data-registry-in-a-box/), [Open, benchmarked algorithms for lines of therapy and progression from routine data](https://onco.cc/ideas/idea-data-open-line-of-therapy-algorithms/), [Patient-reported symptoms captured as standard structured data in every clinic](https://onco.cc/ideas/idea-data-pro-as-structured-standard/), [Patients told which AI is used in their care, in plain language](https://onco.cc/ideas/idea-data-patient-facing-model-cards/), [Pay for cancer AI only when it has outcome evidence, then pay properly](https://onco.cc/ideas/idea-data-ai-reimbursement-tied-to-outcomes/), [Payers fund cancer drugs conditionally on a registry with a pre-specified analysis](https://onco.cc/ideas/idea-data-coverage-with-evidence-development/), [Point-of-care randomisation built into the oncology record](https://onco.cc/ideas/idea-data-point-of-care-randomisation/), [Pre-registration and results reporting for real-world cancer studies](https://onco.cc/ideas/idea-data-observational-study-registration/), [Privacy-preserving linkage tokens for every cancer data holder](https://onco.cc/ideas/idea-data-privacy-preserving-linkage-tokens/), [Public data-quality scorecards for every cancer centre](https://onco.cc/ideas/idea-data-quality-scorecards/), [Public procurement clauses banning data export fees and lock-in](https://onco.cc/ideas/idea-data-procurement-open-api-clauses/), [Publicly funded cancer AI must release open weights and model cards](https://onco.cc/ideas/idea-data-open-weights-for-public-funded-ai/), [Randomised trials of how to spread proven cancer treatments, not just what works](https://onco.cc/ideas/idea-data-implementation-trials-programme/), [Real-time guideline-concordance feedback for every cancer centre](https://onco.cc/ideas/idea-data-guideline-concordance-dashboards/), [Real-world dose intensity and toxicity monitoring to revise labelled doses](https://onco.cc/ideas/idea-data-real-world-dose-intensity/), [Reassess cancer drug prices at three years using real-world outcomes](https://onco.cc/ideas/idea-data-outcome-based-price-reassessment/), [Red-team programmes that attack cancer AI before patients do](https://onco.cc/ideas/idea-data-ai-red-team-programme/), [Registry-based randomised trials for oncology comparative effectiveness](https://onco.cc/ideas/idea-data-registry-based-rcts/), [Require stage-shift or interval-cancer endpoints for AI in cancer screening](https://onco.cc/ideas/idea-data-ai-screening-endpoints/), [Round-the-clock remote treatment-planning hubs for clinics without physicists](https://onco.cc/ideas/idea-acc-remote-planning-hubs/), [Rules for retiring cancer AI when performance drops or the standard of care moves](https://onco.cc/ideas/idea-data-ai-decommissioning-rules/), [Send the code to the data: a federated analytics network of cancer centres](https://onco.cc/ideas/idea-data-federated-analytics-network/), [Sequestered, prospectively collected benchmark datasets that no one can train on](https://onco.cc/ideas/idea-data-sequestered-prospective-benchmarks/), [Simulate each hospital's cancer pathway as a queue to find and remove the waits](https://onco.cc/ideas/idea-acc-pathway-capacity-simulation/), [Standards for external control arms built from federated real-world data](https://onco.cc/ideas/idea-data-external-control-arm-standard/), [Structured, coded radiology reports for cancer response instead of free text](https://onco.cc/ideas/idea-data-structured-radiology-response/), [Subscribable alerts when the standard of care changes for a patient's situation](https://onco.cc/ideas/idea-data-standard-of-care-change-alerts/), [Toxicity-management decision support for nurses and pharmacists](https://onco.cc/ideas/idea-data-toxicity-cds-for-nurses/), [Update hospital order sets within 30 days of a guideline change](https://onco.cc/ideas/idea-data-order-set-defaults-30-days/), [Validate real-world progression against central imaging review](https://onco.cc/ideas/idea-data-rwpfs-validation-programme/), [Wearable activity data as a validated real-world endpoint](https://onco.cc/ideas/idea-data-wearable-endpoints-validation/)
- institutions: [Arc Institute](https://onco.cc/institutions/arc-institute/), [Cancer Center at Illinois](https://onco.cc/institutions/cancer-center-at-illinois/), [Cedars-Sinai Cancer](https://onco.cc/institutions/cedars-sinai-cancer/), [Chan Zuckerberg Biohub](https://onco.cc/institutions/cz-biohub/), [Clinical Data Interchange Standards Consortium](https://onco.cc/institutions/cdisc/), [EMBL's European Bioinformatics Institute](https://onco.cc/institutions/embl-ebi/), [Emerson Collective](https://onco.cc/institutions/emerson-collective/), [Herbert Irving Comprehensive Cancer Center, Columbia University](https://onco.cc/institutions/columbia-hicc/), [HL7 International](https://onco.cc/institutions/hl7/), [Indian Council of Medical Research](https://onco.cc/institutions/icmr/), [Indian Institute of Science](https://onco.cc/institutions/iisc/), [Institute for Protein Design (University of Washington)](https://onco.cc/institutions/institute-for-protein-design/), [Intermountain Health Cancer Center](https://onco.cc/institutions/intermountain-cancer/), [Laura and Isaac Perlmutter Cancer Center at NYU Langone Health](https://onco.cc/institutions/nyu-perlmutter/), [National Cancer Registry Programme (ICMR-NINE, Bengaluru)](https://onco.cc/institutions/icmr-ncrp/), [NCT/UCC Dresden, University Hospital Carl Gustav Carus](https://onco.cc/institutions/nct-dresden/), [Ontario Institute for Cancer Research](https://onco.cc/institutions/oicr/), [Providence Health & Services](https://onco.cc/institutions/providence-health/), [The Mark Foundation for Cancer Research](https://onco.cc/institutions/mark-foundation/), [Vivli](https://onco.cc/institutions/vivli/), [Wellcome](https://onco.cc/institutions/wellcome/), [Yale School of Medicine / Yale Cancer Center](https://onco.cc/institutions/yale-school-of-medicine/), [Yale University Open Data Access (YODA) Project](https://onco.cc/institutions/yoda-project/)
- roadmaps: [AI in oncology roadmap: pattern readers → foundation models → agents in the workflow](https://onco.cc/roadmaps/ai-oncology-roadmap/), [AI in the oncology clinic: from narrow cleared tools to multimodal decision support](https://onco.cc/roadmaps/ai-oncology-clinic/), [Virtual cell roadmap: from bulk omics to a predictive model of a cancer cell](https://onco.cc/roadmaps/virtual-cell/)

---
JSON: https://onco.cc/api/v1/entities/ai-computation.json